BeOne Medicines AG (FRA:49BA)
Germany
· Delayed Price · Currency is EUR | Market Cap | 30.71B |
| Revenue (ttm) | 4.24B |
| Net Income (ttm) | 58.43M |
| Shares Out | n/a |
| EPS (ttm) | 0.50 |
| PE Ratio | 525.71 |
| Forward PE | 72.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 16 |
| Open | 284.00 |
| Previous Close | 284.00 |
| Day's Range | 282.00 - 284.00 |
| 52-Week Range | 166.00 - 322.00 |
| Beta | n/a |
| RSI | 40.70 |
| Earnings Date | Mar 27, 2026 |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as... [Read more]
Financial Performance
In 2024, BeOne Medicines AG's revenue was 27.81 billion, an increase of 59.51% compared to the previous year's 17.43 billion. Losses were -4.71 billion, -24.72% less than in 2023.
Financial numbers in CNY Financial StatementsNews
BeiGene Non-GAAP EPADS of $2.65, revenue of $1.4B beats by $40M
BeiGene Q3 2025 Earnings Preview
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...